110 related articles for article (PubMed ID: 37316362)
21. Resection or transplantation for early hepatocellular carcinoma in a cirrhotic liver: does size define the best oncological strategy?
Adam R; Bhangui P; Vibert E; Azoulay D; Pelletier G; Duclos-Vallée JC; Samuel D; Guettier C; Castaing D
Ann Surg; 2012 Dec; 256(6):883-91. PubMed ID: 23108125
[TBL] [Abstract][Full Text] [Related]
22. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.
Mazzaferro V; Sposito C; Zhou J; Pinna AD; De Carlis L; Fan J; Cescon M; Di Sandro S; Yi-Feng H; Lauterio A; Bongini M; Cucchetti A
Gastroenterology; 2018 Jan; 154(1):128-139. PubMed ID: 28989060
[TBL] [Abstract][Full Text] [Related]
23. Validation of Metroticket Score in the Preoperative Period of Liver Transplantation for Hepatocellular Carcinoma.
de Ataide EC; Perales SR; Teramoto FD; Garcia A; de Macedo PRA; Cunha-Silva M; Sevá-Pereira T; Foratto A; Fernandes DP; Marcondes DC; Meneses CJ; Meneses CJ; da Costa LBE; Neto FC; Boin ISFSF
Transplant Proc; 2022 Jun; 54(5):1308-1309. PubMed ID: 35534281
[TBL] [Abstract][Full Text] [Related]
24. A retrospective single-centre analysis of the oncological impact of LI-RADS classification applied to Metroticket 2.0 calculator in liver transplantation: every nodule matters.
Centonze L; Di Sandro S; Lauterio A; De Carlis R; Sgrazzutti C; Ciulli C; Vella I; Vicentin I; Incarbone N; Bagnardi V; Vanzulli A; De Carlis L
Transpl Int; 2021 Sep; 34(9):1712-1721. PubMed ID: 34448275
[TBL] [Abstract][Full Text] [Related]
25. The AGH score is a predictor of disease-free survival and targeted therapy efficacy after liver transplantation in patients with hepatocellular carcinoma.
Li JH; Chen T; Xing H; Li RD; Shen CH; Zhang QB; Tao YF; Wang ZX
Hepatobiliary Pancreat Dis Int; 2023 Jun; 22(3):245-252. PubMed ID: 35534342
[TBL] [Abstract][Full Text] [Related]
26. Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma.
Halazun KJ; Rosenblatt RE; Mehta N; Lai Q; Hajifathalian K; Gorgen A; Brar G; Sasaki K; Doyle MBM; Tabrizian P; Agopian VG; Najjar M; Ivanics T; Samstein B; Brown RS; Emond JC; Yao F; Lerut J; Rossi M; Mennini G; Iesari S; Finkenstedt A; Schaefer B; Mittler J; Hoppe-Lotichius M; Quintini C; Aucejo F; Chapman W; Sapisochin G
JAMA Surg; 2021 Jun; 156(6):559-567. PubMed ID: 33950167
[TBL] [Abstract][Full Text] [Related]
27. A Simple Measure of Hepatocellular Carcinoma Burden Predicts Tumor Recurrence After Liver Transplantation: The Recurrent Hepatocellular Carcinoma-Initial, Maximum, Last Classification.
Vutien P; Dodge J; Bambha KM; Nordstrom EM; Gralla J; Campbell K; Levek C; Nydam T; Fix O; Ioannou G; Biggins SW
Liver Transpl; 2019 Apr; 25(4):559-570. PubMed ID: 30706653
[TBL] [Abstract][Full Text] [Related]
28. The role of preoperative albumin-bilirubin grade for oncological risk stratification in liver transplant patients with hepatocellular carcinoma.
Kornberg A; Witt U; Schernhammer M; Kornberg J; Müller K; Friess H; Thrum K
J Surg Oncol; 2019 Dec; 120(7):1126-1136. PubMed ID: 31578753
[TBL] [Abstract][Full Text] [Related]
29. The "No-touch" technique improves the survival of patients with advanced hepatocellular carcinomas treated by liver transplantation: A single-center prospective randomized controlled trial.
Lin X; Xiao M; Gu YJ; Zhu HK; Li MX; Zhuang L; Zheng SS; Li QY
Hepatobiliary Pancreat Dis Int; 2023 Jun; 22(3):253-262. PubMed ID: 35568681
[TBL] [Abstract][Full Text] [Related]
30. Liver resection for hepatocellular carcinoma ≤3 cm: results of an Italian multicenter study on 588 patients.
Giuliante F; Ardito F; Pinna AD; Sarno G; Giulini SM; Ercolani G; Portolani N; Torzilli G; Donadon M; Aldrighetti L; Pulitanò C; Guglielmi A; Ruzzenente A; Capussotti L; Ferrero A; Calise F; Scuderi V; Federico B; Nuzzo G
J Am Coll Surg; 2012 Aug; 215(2):244-54. PubMed ID: 22634119
[TBL] [Abstract][Full Text] [Related]
31. Prognostic factors of disease-free and overall survival in patients with hepatocellular carcinoma undergoing partial hepatectomy in curative intent.
Lurje G; Bednarsch J; Czigany Z; Amygdalos I; Meister F; Schöning W; Ulmer TF; Foerster M; Dejong C; Neumann UP
Langenbecks Arch Surg; 2018 Nov; 403(7):851-861. PubMed ID: 30267147
[TBL] [Abstract][Full Text] [Related]
32. Propensity-Matched Analysis of Patients with Mixed Hepatocellular-Cholangiocarcinoma and Hepatocellular Carcinoma Undergoing Liver Transplantation.
Lunsford KE; Court C; Seok Lee Y; Lu DS; Naini BV; Harlander-Locke MP; Busuttil RW; Agopian VG
Liver Transpl; 2018 Oct; 24(10):1384-1397. PubMed ID: 29573187
[TBL] [Abstract][Full Text] [Related]
33. The Matching Status Between Donor and Recipient Hepatitis B Seroepidemiology Makes a Difference in Liver Transplantation for Hepatocellular Carcinoma.
Lu D; Yang F; Zhuo J; Yang M; Lin Z; Jin P; Cai X; Cen B; Wang J; Wei X; Zheng S; Xu X
Clin Transl Gastroenterol; 2020 May; 11(5):e00168. PubMed ID: 32358239
[TBL] [Abstract][Full Text] [Related]
34. Yes-associated protein expression is a predictive marker for recurrence of hepatocellular carcinoma after liver transplantation.
Li H; Wang S; Wang G; Zhang Z; Wu X; Zhang T; Fu B; Chen G
Dig Surg; 2014; 31(6):468-78. PubMed ID: 25632982
[TBL] [Abstract][Full Text] [Related]
35. Clinical outcomes and risk factors of hepatocellular carcinoma treated by liver transplantation: A multi-centre comparison of living donor and deceased donor transplantation.
Hu Z; Qian Z; Wu J; Zhou J; Zhang M; Zhou L; Zheng S
Clin Res Hepatol Gastroenterol; 2016 Jun; 40(3):315-326. PubMed ID: 26382281
[TBL] [Abstract][Full Text] [Related]
36. Impact of donor sex on hepatocellular carcinoma recurrence in liver transplantation after brain death.
Nakamura T; Sasaki K; Kojima L; Teo R; Inaba Y; Yamamoto T; Kimura S; Dageforde LA; Yeh H; Elias N; Bozorgzadeh A; Kawai T; Markmann JF
Clin Transplant; 2023 Aug; 37(8):e14989. PubMed ID: 37039506
[TBL] [Abstract][Full Text] [Related]
37. Risk of posttransplant hepatocellular carcinoma recurrence is greater in recipients with higher platelet counts in living donor liver transplantation.
Han S; Lee S; Yang JD; Leise MD; Ahn JH; Kim S; Jung K; Gwak MS; Kim GS; Ko JS
Liver Transpl; 2018 Jan; 24(1):44-55. PubMed ID: 29024412
[TBL] [Abstract][Full Text] [Related]
38. Dropout rate from the liver transplant waiting list because of hepatocellular carcinoma progression in hepatitis C virus-infected patients treated with direct-acting antivirals.
Zanetto A; Shalaby S; Vitale A; Mescoli C; Ferrarese A; Gambato M; Franceschet E; Germani G; Senzolo M; Romano A; Angeli P; Rugge M; Farinati F; Forton DM; Cillo U; Burra P; Russo FP
Liver Transpl; 2017 Sep; 23(9):1103-1112. PubMed ID: 28544587
[TBL] [Abstract][Full Text] [Related]
39. Antiviral therapy improves post-operative survival outcomes in patients with HBV-related hepatocellular carcinoma of less than 3 cm - A retrospective cohort study.
Wang ZY; Tao QF; Wang ZH; Lin KY; Huang G; Yang Y; Zhou WP; Lau WY
Am J Surg; 2020 Apr; 219(4):717-725. PubMed ID: 31266631
[TBL] [Abstract][Full Text] [Related]
40. Gadoxetic acid-enhanced MRI as a predictor of recurrence of HCC after liver transplantation.
Lee S; Kim KW; Jeong WK; Kim MJ; Choi GH; Choi JS; Song GW; Lee SG
Eur Radiol; 2020 Feb; 30(2):987-995. PubMed ID: 31471754
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
